Market Intel: Intragastric Balloons And Other Innovations To Inflate Weight Loss Devices Market
The global market for minimally invasive weight loss devices is expected to grow to $290m by 2021, a CAGR of 16%, driven in large part by the rising obesity epidemic and associated Type 2 diabetes. Meddevicetracker expects that enhancements and innovations, particularly in the growing intragastric balloon market, and emerging technologies by smaller companies, will lead the growth in the overall weight loss devices market. In this feature, we'll take a closer look at the overall market and regional landscape and take a deep dive into the fastest-growing intragastric balloon segment, providing key insights from a bariatric surgeon on the pros and cons of these technologies.
You may also be interested in...
Starts & Stops: Check-Cap Starts US Trial; Venous Valve Study Begins; CorMatrix Looks At ‘Living’ Tricuspid Valve
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by MedDeviceTracker. This edition covers trial announcements from Feb. 11 through Feb. 24, including announcements from CorMatrix Cardiovascular, Hancock Jaffe Laboratories, Toray Industries, Spectral Medical, GI Dynamics, and Check-Cap.
Obesity Firm Allurion Preps For Global Expansion, US Trial With Changes At Top
Intragastric balloon-maker Allurion is making some major changes in its executive suite to support its plan to expand its market reach.
EnteroMedics Inflates Neuromod-Obesity Offering With ReShape Balloon
The deal, worth $61m in cash and stock, will add ReShape's Dual Weight Loss Balloon to EnteroMedics' vBloc neurometabolic therapy and Gastric Vest System for the treatment of obesity.